Search research articles
Contact Us
Filters
Showing results (41-50 of 47) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 47 results.
JMIR Mhealth and Uhealth
|
March 11, 2017
Remote Monitoring of Hypertension Diseases in Pregnancy: A Pilot Study
Dorien Lanssens, Thijs Vandenberk, Christophe Jp Smeets, et al.
Frontiers in Immunology
|
January 10, 2018
Development of Endotoxin Tolerance Does Not Influence the Response to a Challenge with the Mucosal Live-Attenuated Influenza Vaccine in Humans <i>In Vivo</i>
Rebecca M Koch, Matthijs Kox, Eleonora J M Thijs, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
June 11, 2026
Real-World Impact of UGT1A1 Genotype-Guided Irinotecan Dosing on Severe Toxicity and Hospitalization: A Multicenter Study
Niels Heersche, Sofía L J Peeters, Doortje Böhm, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
September 25, 2024
Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial
Giorgio Valabrega, Matthew A Powell, Sakari Hietanen, et al.
The Lancet Regional Health. Europe
|
March 4, 2026
Survival of patients with colorectal or pancreatic cancer who received <i>UGT1A1</i> genotype-guided dosing of irinotecan in the Netherlands (2017-2024): a retrospective, multicentre cohort study
Sofía L J Peeters, Niels Heersche, Doortje Böhm, et al.
BMC Systems Biology
|
January 20, 2011
A community effort towards a knowledge-base and mathematical model of the human pathogen Salmonella Typhimurium LT2
Ines Thiele, Daniel R Hyduke, Benjamin Steeb, et al.
Gynecologic Oncology
|
November 12, 2024
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)
Matthew A Powell, David Cibula, David M O'Malley, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 47) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 47 results.
JMIR Mhealth and Uhealth
|
March 11, 2017
Remote Monitoring of Hypertension Diseases in Pregnancy: A Pilot Study
Dorien Lanssens, Thijs Vandenberk, Christophe Jp Smeets, et al.
Frontiers in Immunology
|
January 10, 2018
Development of Endotoxin Tolerance Does Not Influence the Response to a Challenge with the Mucosal Live-Attenuated Influenza Vaccine in Humans <i>In Vivo</i>
Rebecca M Koch, Matthijs Kox, Eleonora J M Thijs, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
June 11, 2026
Real-World Impact of UGT1A1 Genotype-Guided Irinotecan Dosing on Severe Toxicity and Hospitalization: A Multicenter Study
Niels Heersche, Sofía L J Peeters, Doortje Böhm, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
September 25, 2024
Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial
Giorgio Valabrega, Matthew A Powell, Sakari Hietanen, et al.
The Lancet Regional Health. Europe
|
March 4, 2026
Survival of patients with colorectal or pancreatic cancer who received <i>UGT1A1</i> genotype-guided dosing of irinotecan in the Netherlands (2017-2024): a retrospective, multicentre cohort study
Sofía L J Peeters, Niels Heersche, Doortje Böhm, et al.
BMC Systems Biology
|
January 20, 2011
A community effort towards a knowledge-base and mathematical model of the human pathogen Salmonella Typhimurium LT2
Ines Thiele, Daniel R Hyduke, Benjamin Steeb, et al.
Gynecologic Oncology
|
November 12, 2024
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)
Matthew A Powell, David Cibula, David M O'Malley, et al.
Page
of 5